Liu Yan-Rong, Liu Qiang
Department of Osteopathy, First Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China.
Chin J Traumatol. 2012;15(2):86-91.
To assess the efficacy and safety of mouse nerve growth factor (mNGF) in patients with peripheral nerve injury.
Such electronic database as Cochrane Library (Issue 1, 2011), Medline (1950-2011), Embase (1980-2011), National Knowledge Infrastructure (1979-2011) were searched and meanwhile relevant journals such as Chinese Journal of Orthopaedics, Chinese Journal of Microsurgery, Chinese Journal of Neurosurgery, etc were searched as well to collect all randomized controlled trials and quasi-randomi- zed controlled trials of mNGF on patients with peripheral nerve injury. The quality of included studies was assessed according to the criteria recommended by the Cochrane Handbook for Systematic Reviews of Interventions and the data were extracted by two reviewers independently. Meta-analysis was conducted by RevMan 5.1 software.
Forty-one studies involving 3 304 patients with peripheral nerve injury were included. The results of meta-analysis showed that: (1) the total effective rate of peripheral nerve injury treatment in mNGF group was ob- viously higher than that in control group (OR equal to 6.36, 95% CI 4.96-8.15, P less than 0.01); (2) the scores of activities of daily living (ADL) in mNGF group was significantly higher than that in control group (weighted mean difference equal to 1.97, 95% CI 1.33-2.61, P less than 0.01); (3) the incidence of adverse reaction in mNGF group was higher than that in control group, (OR equal to 1.66, 95% CI 1.61-2.38, P equal to 0.006), but the adverse effects were mild, which could be relieved without specific treatment or just given symptomatic treatment, and disappeared at the end of treatment.
The mNGF therapy is effective for peripheral nerve injury. It can obviously improve patient's ADL. Though the incidence of adverse reaction in mNGF treatment group is higher than that in control group, this does not influence the treatment outcomes.
评估小鼠神经生长因子（mNGF）治疗周围神经损伤患者的疗效及安全性。
检索Cochrane图书馆（2011年第1期）、Medline（1950 - 2011年）、Embase（1980 - 2011年）、中国知网（1979 - 2011年）等电子数据库，同时检索《中华骨科杂志》《中华显微外科杂志》《中华神经外科杂志》等相关期刊，收集所有mNGF治疗周围神经损伤患者的随机对照试验和半随机对照试验。按照Cochrane系统评价干预措施手册推荐的标准评估纳入研究的质量，由两名评价员独立提取数据。采用RevMan 5.1软件进行Meta分析。
纳入41项研究，共3304例周围神经损伤患者。Meta分析结果显示：（1）mNGF组周围神经损伤治疗的总有效率明显高于对照组（OR = 6.36，95%CI 4.96 - 8.15，P < 0.01）；（2）mNGF组日常生活活动能力（ADL）评分显著高于对照组（加权均数差 = 1.97，95%CI 1.33 - 2.61，P < 0.01）；（3）mNGF组不良反应发生率高于对照组（OR = 1.66，95%CI 1.61 - 2.38，P = 0.
